Edward Azar, DPM
Foot & Ankle Surgery · Brooklyn, NYNPI 1003291832
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Paratek Pharmaceuticals, Inc. at 45.9% of the total. 2025 is the largest year on record at $9,314, more than ten times the $861 reported in 2019. Among foot & ankle surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $57.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$8K
- Mylan Specialty L.p.$2K
- Smith+Nephew$1K
- AbbVie$1K
- Kerecis Limited$870
- Stryker$723
- plus $3K from 28 others
Across 18 payments — averaging $11,562 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Organogenesis Inc.$206K
- Regeneron$2K
What the payments were for
- Speaking & faculty fees$5,46030%
- Travel & lodging$3,31918%
- Food & beverage$9,25651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 88 | $8,277 |
| Mylan Specialty L.p. | 6 | $1,988 |
| Smith+Nephew | 56 | $1,408 |
| AbbVie(2 entities) | 72 | $1,333 |
| Kerecis Limited | 4 | $870 |
| Stryker(2 entities) | 19 | $723 |
| Angiodynamics, Inc. | 6 | $573 |
| Cardiovascular Systems Inc. | 5 | $506 |
| Amgen(2 entities) | 7 | $325 |
| Biotissue Holdings Inc. | 1 | $318 |
| Averitas Pharma Inc. | 5 | $298 |
| Linvatec Corporation | 2 | $226 |
| Amniox Medical, Inc. | 3 | $146 |
| Melinta Therapeutics, LLC | 6 | $136 |
| Inari Medical, Inc. | 2 | $125 |
| Paragon 28, Inc. | 1 | $125 |
| Tactile Systems Technology Inc | 6 | $103 |
| Mimedx Group, Inc. | 2 | $95 |
| GRT US Holding, Inc. | 3 | $56 |
| Johnson & Johnson | 2 | $54 |
| Advanced Oxygen Therapy Inc. | 1 | $54 |
| Zimmer Biomet | 2 | $44 |
| Bioventus LLC | 1 | $36 |
| DJO, LLC | 2 | $30 |
| Nabriva Therapeutics, PLC | 2 | $28 |
| Nevro Corp. | 1 | $23 |
| Integra Lifesciences Corporation | 1 | $23 |
| Organogenesis Inc. | 1 | $20 |
| Solventum Corporation | 1 | $20 |
| Osiris Therapeutics Inc. | 1 | $18 |
| Abbott | 1 | $17 |
| Venclose Inc. | 1 | $15 |
| KCI USA, Inc. | 1 | $12 |
| Electronic Waveform Lab, Inc. | 2 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$6,828
- Kerecis Omega3 SurgiClose$1,450
- Kerecis Omega3 Marigen$1,128
- Kerecis Omega3 GraftGuide$844
- Prokera$318
- AmnioGraft$318
- AmnioGuard$318
- FLOWTRIEVER CATHETER, S$273
- CT THROMBECTOMY SYSTEM KIT$273
- Diamondback Peripheral$269
- Kerecis Omega3 Wound$265
- Kerecis Omega3 Surgibind$265
- Oasis$257
- Stravix$257
- Auryon Laser System 100-120 Vac$253
- Qutenza$236
- KRYSTEXXA$226
- DALVANCE$225
- AUGMENT$167
- BioBrace 23mm$166
How this compares
$18,035 in reported general payments places this provider in the 90th percentile of 652 foot & ankle surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuzyraOmadacycline Tosylate | 39 | $293,727 |
| Tavaborole | 176 | $201,527 |
| SantylCollagenase Clostridium Hist. | 16 | $34,222 |
| Econazole Nitrate | 110 | $2,511 |
| Cephalexin | 115 | $1,214 |
| Lidocaine | 36 | $803 |
| Diclofenac Sodium | 25 | $415 |
| Gabapentin | 49 | $361 |
| Ibuprofen | 51 | $312 |
| Duloxetine Hcl | 33 | $297 |
| Terbinafine Hcl | 17 | $248 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 22 | $245 |
| Temazepam | 13 | $213 |
| Ciclopirox | 11 | $190 |
| Ciprofloxacin Hcl | 18 | $186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Paratek Pharmaceuticals, Inc.Nuzyra | $8,277 | $293,72739 claims |
| Smith+NephewSantyl | $1,408 | $34,22216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 652 foot & ankle surgery providers in New York.
Other foot & ankle surgery in Brooklyn
- Yury RotshteynBrooklyn$43K
- Mario VoloshinBrooklyn$33K
- Bryan MakowerBrooklyn$28K
- Amit GandhiBrooklyn$21K
- James McWilliamHarrison$4.7M
- Jonathan DelandNew York$4M
- George Vitole Roy$2.5M
- Constantine DemetracopoulosNew York$888K
- Anne JohnsonNew York$815K
- Scott EllisNew York$597K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.